RMD vs MDLN vs WST
161 measures in 16 categories, one definition each, computed from filings and market data.
RMD81.9
ResMed Inc.
Healthcare · Medical - Instruments & Supplies
$238.97 −1.35%$33.6B mkt cap
Score DNA
MDLN42.6
Medline Inc.
Healthcare · Medical - Instruments & Supplies
$35.96 −1.67%$31.5B mkt cap
Score DNA
WST71.5
West Pharmaceutical Services, Inc.
Healthcare · Medical - Instruments & Supplies
$384.02 +0.21%$27.0B mkt cap
Score DNA
Price, rebased to 100 three years ago
RMD MDLN WST · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 3 | 0 | 0 |
| Last Congress purchase | 2026-09-11 | — | — |
| 13F net change in holders | −51 | +94 | — |
| ETFs adding shares, 30d | 1,058 | 543 | 1,073 |
| ETFs trimming, 30d | 859 | 332 | 867 |
| Net ETF funds, 30d | +199 | +211 | +206 |
Valuation
16 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| P/E (TTM) | 22.1x
27th
|
85.5x
73rd
|
47.8x
53rd
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 1.10
43rd
|
— | 9.92
100th
|
| Price / sales | 5.9x
79th
|
1.4x
21st
|
8.1x
88th
|
| Price / book | 5.1x
71st
|
2.7x
42nd
|
9.0x
92nd
|
| Price / tangible book | 8.8x
67th
|
— | 8.9x
73rd
|
| Price / free cash flow | 11.6x
5th
|
21.2x
38th
|
61.9x
81st
|
| Price / operating cash flow | 10.6x
14th
|
23.3x
64th
|
40.8x
77th
|
| Enterprise value | $33.0B
88th
|
$41.5B
92nd
|
$26.9B
84th
|
| EV / sales | 5.8x
79th
|
1.8x
21st
|
8.1x
88th
|
| EV / EBITDA | 15.3x
30th
|
24.1x
55th
|
30.9x
70th
|
| EV / EBIT | 17.1x
18th
|
40.1x
71st
|
39.0x
59th
|
| EV / free cash flow | 11.4x
5th
|
27.8x
38th
|
61.6x
76th
|
| Earnings yield | 4.5%
84th
|
1.2%
56th
|
2.1%
68th
|
| FCF yield | 8.6%
96th
|
4.7%
68th
|
1.6%
32nd
|
| Operating cash flow yield | 9.4%
88th
|
4.3%
44th
|
2.5%
32nd
|
| Graham number (per share) | $103.63
100th
|
$11.38
14th
|
$86.46
86th
|
Profitability (TTM)
12 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| Gross margin | 61.2%
76th
|
25.0%
4th
|
36.8%
20th
|
| EBITDA margin | 38.2%
96th
|
7.5%
33rd
|
26.2%
79th
|
| Operating margin | 33.5%
100th
|
5.4%
33rd
|
20.6%
79th
|
| EBIT margin | 34.0%
100th
|
4.5%
38th
|
20.7%
79th
|
| Net margin | 26.9%
96th
|
1.6%
46th
|
17.0%
83rd
|
| NOPAT margin | 26.6%
100th
|
4.1%
42nd
|
16.4%
79th
|
| FCF margin | 51.1%
100th
|
6.5%
38th
|
13.1%
71st
|
| Operating cash flow margin | 55.8%
100th
|
5.9%
21st
|
19.9%
83rd
|
| R&D / revenue | 6.7%
58th
|
0.0%
0th
|
2.2%
12th
|
| SG&A / revenue | 19.7%
12th
|
16.6%
4th
|
12.8%
0th
|
| Stock comp / revenue | 3.2%
72nd
|
0.1%
4th
|
1.0%
28th
|
| Effective tax rate | 20.6%
32nd
|
23.8%
84th
|
20.6%
28th
|
Returns on capital
11 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| ROE (on average equity) | 24.3%
96th
|
3.2%
62nd
|
19.1%
92nd
|
| ROA | 17.8%
100th
|
0.9%
48th
|
14.1%
92nd
|
| ROIC | 25.3%
92nd
|
4.4%
56th
|
19.0%
80th
|
| ROCE | 25.4%
96th
|
2.8%
44th
|
20.1%
92nd
|
| Return on tangible assets | 22.4%
100th
|
2.6%
44th
|
17.2%
88th
|
| Cash ROIC (OCF / invested capital) | 53.1%
100th
|
6.3%
28th
|
23.1%
84th
|
| Gross profitability (GP / assets) | 38.6%
80th
|
14.7%
12th
|
30.0%
64th
|
| ROIC, 3-yr average | 21.8%
100th
|
— | 16.6%
90th
|
| ROIC, 5-yr average | 26.2%
100th
|
— | 21.4%
95th
|
| ROE, 5-yr average | 22.5%
100th
|
— | 20.6%
95th
|
| Incremental ROIC | 66.0%
62nd
|
— | 225.8%
92nd
|
Growth
17 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| Revenue growth (TTM YoY) | 9.9%
57th
|
— | 12.4%
74th
|
| Revenue growth (QoQ) | 2.3%
20th
|
4.5%
48th
|
3.2%
24th
|
| Revenue CAGR, 3 yr | 10.2%
76th
|
— | 5.1%
62nd
|
| Revenue CAGR, 5 yr | 12.1%
79th
|
— | 5.7%
47th
|
| Gross profit CAGR, 3 yr | 13.6%
81st
|
— | 3.8%
57th
|
| Operating income CAGR, 3 yr | 18.7%
64th
|
— | -0.8%
29th
|
| Net income growth (TTM YoY) | 8.8%
30th
|
— | 15.8%
40th
|
| Net income CAGR, 3 yr | 19.3%
64th
|
— | 2.9%
36th
|
| EPS growth (TTM YoY) | 10.3%
30th
|
— | 18.3%
40th
|
| EPS CAGR, 3 yr | 20.0%
64th
|
— | 4.8%
36th
|
| EPS CAGR, 5 yr | 26.5%
91st
|
— | 2.9%
55th
|
| FCF growth (TTM YoY) | 74.2%
82nd
|
— | 27.0%
59th
|
| FCF CAGR, 3 yr | 72.9%
100th
|
— | 3.3%
21st
|
| Operating cash flow CAGR, 3 yr | 65.7%
88th
|
— | -2.2%
19th
|
| Book value CAGR, 3 yr | 17.5%
100th
|
— | 4.8%
76th
|
| Dividend CAGR, 3 yr | 26.1%
100th
|
— | 3.2%
62nd
|
| Sustainable growth rate | 14.5%
79th
|
3.2%
43rd
|
17.0%
86th
|
Margin history & stability
7 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| Gross margin, 3-yr average | 58.9%
64th
|
— | 36.0%
18th
|
| Operating margin, 3-yr average | 31.5%
100th
|
— | 21.1%
86th
|
| Net margin, 3-yr average | 25.3%
95th
|
— | 17.2%
86th
|
| FCF margin, 3-yr average | 36.9%
100th
|
— | 12.4%
68th
|
| Revenue stability (0-1) | 1.00
100th
|
— | 0.90
57th
|
| Earnings stability (0-1) | 0.97
100th
|
— | 0.07
13th
|
| Margin stability (0-1) | 0.96
45th
|
— | 0.96
36th
|
Liquidity (latest quarter)
7 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| Cash & short-term investments | $1.5B
88th
|
$2.7B
96th
|
$435.8M
68th
|
| Net cash (− = net debt) | $643.3M
96th
|
−$10.0B
4th
|
$123.7M
80th
|
| Working capital | $2.9B
88th
|
$9.0B
100th
|
$1.2B
84th
|
| Current ratio | 3.10
64th
|
4.33
76th
|
2.82
60th
|
| Quick ratio | 2.42
64th
|
2.61
68th
|
2.12
52nd
|
| Cash ratio (cash + ST investments / current liabilities) | 1.05
56th
|
0.99
52nd
|
0.68
48th
|
| Defensive interval (days) | 584 days
76th
|
508 days
72nd
|
782 days
92nd
|
Leverage & solvency (latest quarter)
13 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| Total debt | $825.9M
48th
|
$12.6B
96th
|
$312.1M
36th
|
| Debt / equity | 0.13
25th
|
1.09
83rd
|
0.10
21st
|
| Net debt / equity | −0.10
33rd
|
0.86
79th
|
−0.04
42nd
|
| Debt / assets | 9.2%
24th
|
32.1%
68th
|
7.7%
20th
|
| Debt / capital | 11.1%
25th
|
52.2%
83rd
|
9.5%
21st
|
| Debt / EBITDA | 0.38
10th
|
7.34
85th
|
0.36
5th
|
| Net debt / EBITDA | −0.30
25th
|
5.79
80th
|
−0.14
30th
|
| Interest coverage (EBIT / interest) | 66.2x
95th
|
2.1x
43rd
|
6,896.0x
100th
|
| Cash interest coverage | 108.8x
95th
|
2.7x
24th
|
6,622.0x
100th
|
| Debt payback (years of OCF) | 0.3 yrs
5th
|
9.3 yrs
91st
|
0.5 yrs
9th
|
| Liabilities / assets | 26.6%
20th
|
51.5%
68th
|
26.6%
24th
|
| IS credit model rating | AAA | BB+ | AAA |
| Implied credit spread (bps) | 50
0th
|
400
60th
|
50
0th
|
Efficiency
11 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| Asset turnover | 0.66
72nd
|
0.58
64th
|
0.83
84th
|
| Fixed asset turnover | 7.69
84th
|
4.86
68th
|
0.99
4th
|
| Inventory turnover | 2.3
40th
|
3.7
64th
|
4.8
84th
|
| Receivables turnover | 5.7
32nd
|
6.2
48th
|
5.1
20th
|
| Days sales outstanding | 64 days
68th
|
59 days
52nd
|
71 days
80th
|
| Days inventory outstanding | 156 days
60th
|
100 days
36th
|
75 days
16th
|
| Days payables outstanding | 49 days
40th
|
22 days
4th
|
43 days
24th
|
| Cash conversion cycle (days) | 171 days
68th
|
136 days
56th
|
104 days
32nd
|
| Capex / revenue | 4.7%
62nd
|
— | 6.8%
83rd
|
| Capex / depreciation | 1.14
92nd
|
— | 1.25
96th
|
| Operating expense ratio | 28.2%
21st
|
23.7%
8th
|
17.2%
4th
|
Cash flow & earnings quality
7 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| Operating cash flow / net income | 2.07
60th
|
3.67
87th
|
1.17
13th
|
| FCF / net income | 1.90
60th
|
4.04
87th
|
0.77
13th
|
| FCF / operating cash flow | 91.5%
90th
|
— | 66.0%
43rd
|
| Capex / operating cash flow | 8.5%
10th
|
— | 34.0%
57th
|
| Accruals ratio | -19.1%
12th
|
-2.5%
88th
|
-2.4%
92nd
|
| Sloan accruals ratio | 2.4%
80th
|
14.5%
100th
|
-2.2%
52nd
|
| Earnings quality score (0-1) | 0.75
13th
|
1.00
47th
|
1.00
47th
|
Scores & forensic checks
15 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| IS score | 82
100th
|
43
52nd
|
72
88th
|
| IS profitability | 93
100th
|
16
12th
|
67
88th
|
| IS growth | 55
43rd
|
— | 61
61st
|
| IS value | 63
92nd
|
37
16th
|
41
36th
|
| IS momentum | 81
65th
|
— | 84
70th
|
| IS risk (safety) | 100
72nd
|
50
16th
|
100
72nd
|
| IS quality | 93
100th
|
55
48th
|
88
88th
|
| IS balance sheet | 91
92nd
|
39
24th
|
90
88th
|
| IS earnings quality | 44
40th
|
79
88th
|
72
64th
|
| IS cash flow | 99
100th
|
55
56th
|
73
84th
|
| Piotroski F-score (0-9) | 7
68th
|
4
12th
|
9
96th
|
| Altman Z-score | 10.0
88th
|
1.9
20th
|
17.4
92nd
|
| Beneish M-score | −3.29
17th
|
— | −3.79
9th
|
| Ohlson O-score | −12.34
4th
|
−9.12
32nd
|
−10.58
8th
|
| IS credit score | 96
96th
|
47
36th
|
96
96th
|
Size (TTM)
8 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| Market cap | $33.6B
92nd
|
$31.5B
88th
|
$27.0B
84th
|
| Revenue | $5.7B
76th
|
$22.8B
100th
|
$3.3B
56th
|
| EBITDA | $2.2B
88th
|
$1.7B
84th
|
$870.4M
76th
|
| Net income | $1.5B
96th
|
$369.0M
76th
|
$564.9M
80th
|
| Free cash flow | $2.9B
96th
|
$1.5B
88th
|
$436.9M
72nd
|
| Total assets | $9.0B
68th
|
$39.4B
96th
|
$4.1B
48th
|
| Shareholders' equity | $6.6B
84th
|
$11.6B
92nd
|
$3.0B
60th
|
| Employees | 11,370
48th
|
45,000
96th
|
10,800
44th
|
Price performance
9 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| 1 day | −1.4% | −1.7% | +0.2% |
| 1 week | +3.9% | −0.8% | +4.9% |
| 1 month | +4.6% | +12.0% | +4.7% |
| 3 months | +20.3% | −7.5% | +9.0% |
| 6 months | +4.8% | −24.5% | +40.2% |
| Year to date | −2.2% | −11.5% | +39.0% |
| 1 year | −11.2% | — | +46.1% |
| 3 years, cumulative | +69.2% | — | −1.5% |
| 5 years, cumulative | −2.3% | — | −4.7% |
Technicals
4 measures| Measure | RMD | MDLN | WST |
|---|---|---|---|
| RSI 14 | 66.5 | 55.7 | 65.5 |
| From 52-week high | −13.7% | — | −0.7% |
| From 52-week low | +32.6% | — | +71.5% |
| Beta | 0.75 | -0.41 | 1.12 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17